Global Alpha Capital Management Ltd. Makes New $2.45 Million Investment in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Global Alpha Capital Management Ltd. acquired a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 72,500 shares of the company's stock, valued at approximately $2,446,000. Global Alpha Capital Management Ltd. owned approximately 0.16% of Pacira BioSciences at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of PCRX. Pacer Advisors Inc. increased its stake in shares of Pacira BioSciences by 397,487.4% in the 4th quarter. Pacer Advisors Inc. now owns 1,041,679 shares of the company's stock worth $35,146,000 after purchasing an additional 1,041,417 shares in the last quarter. Rubric Capital Management LP purchased a new stake in shares of Pacira BioSciences in the 3rd quarter worth $14,102,000. Norges Bank purchased a new stake in shares of Pacira BioSciences in the 4th quarter worth $9,542,000. Assenagon Asset Management S.A. boosted its holdings in Pacira BioSciences by 185.2% in the 4th quarter. Assenagon Asset Management S.A. now owns 246,621 shares of the company's stock worth $8,321,000 after buying an additional 160,149 shares during the period. Finally, Hillsdale Investment Management Inc. bought a new position in Pacira BioSciences in the 4th quarter worth $4,521,000. 99.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $57.00 target price on shares of Pacira BioSciences in a report on Wednesday, May 8th. Royal Bank of Canada dropped their target price on shares of Pacira BioSciences from $53.00 to $45.00 and set an "outperform" rating for the company in a report on Friday, March 1st. JPMorgan Chase & Co. assumed coverage on shares of Pacira BioSciences in a report on Thursday, March 7th. They issued an "overweight" rating and a $45.00 target price for the company. TheStreet raised shares of Pacira BioSciences from a "d+" rating to a "c" rating in a report on Thursday, February 29th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $57.00 target price on shares of Pacira BioSciences in a report on Thursday, February 8th. Eleven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $47.40.

Insider Buying and Selling

In related news, Director Gary W. Pace sold 90,000 shares of the stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $30.60, for a total value of $2,754,000.00. Following the sale, the director now directly owns 22,127 shares of the company's stock, valued at approximately $677,086.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Gary W. Pace sold 90,000 shares of the stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $30.60, for a total value of $2,754,000.00. Following the sale, the director now directly owns 22,127 shares of the company's stock, valued at approximately $677,086.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gary W. Pace sold 1,066 shares of the stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $29.67, for a total transaction of $31,628.22. Following the completion of the sale, the director now directly owns 140,384 shares in the company, valued at $4,165,193.28. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by corporate insiders.

Pacira BioSciences Price Performance

Shares of PCRX traded up $0.29 during midday trading on Tuesday, hitting $30.90. 968,512 shares of the company traded hands, compared to its average volume of 603,472. The firm has a 50 day moving average of $28.34 and a 200-day moving average of $29.66. Pacira BioSciences, Inc. has a 52 week low of $25.33 and a 52 week high of $42.63. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of 21.41 and a beta of 0.77. The company has a debt-to-equity ratio of 0.57, a quick ratio of 4.78 and a current ratio of 5.81.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last announced its quarterly earnings results on Thursday, February 29th. The company reported $0.71 EPS for the quarter, meeting analysts' consensus estimates of $0.71. Pacira BioSciences had a net margin of 10.34% and a return on equity of 12.98%. The firm had revenue of $181.24 million during the quarter, compared to the consensus estimate of $180.60 million. On average, analysts forecast that Pacira BioSciences, Inc. will post 2.12 EPS for the current fiscal year.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.